Price (delayed)
$51.155
Market cap
$754.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.74
Enterprise value
$597.98M
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
There are no recent dividends present for TECX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.